Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | OXTR | P30559 | 1/20 | 0.49 |
| ▸ | GRB2 | P62993 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29768799 | 0.84 | ST14 (0.69) | ST14 | |
| SCHEMBL17252023 | 0.84 | TACR1 (0.48) | ST14TACR1HDAC3HDAC4HDAC1 | |
| SCHEMBL17252074 | 0.84 | TACR1 (0.51) | ST14TACR1HDAC4 | |
| SCHEMBL17252024 | 0.83 | TACR1 (0.49) | ST14TACR1OXTRHDAC3HDAC4 | |
| Stylopeptide SCHEMBL31094295 | 0.83 | HDAC4 (0.53) | OXTRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29387556 | 0.83 | ABCB1 (0.57) | OXTRHDAC4 | |
| SCHEMBL29602298 | 0.82 | HDAC4 (0.59) | GRB2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL32676347 | 0.82 | PSMB11 (0.53) | TACR1GRB2 | |
| SCHEMBL30576709 | 0.82 | HDAC4 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29352662 | 0.81 | HDAC8 (0.49) | HDAC4HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3915587-B1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECH BV (NL) | 2026-03-25 | — | — | EP | claimed |
| US-20260000783-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | SAPREME TECHNOLOGIES B.V. (NL) | 2026-01-01 | — | — | US | claimed |
| EP-3897735-B1 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | SAPREME TECH BV (NL) | 2025-10-22 | — | — | EP | claimed |
| EP-4596052-A2 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | Sapreme Technologies B.V. (NL) | 2025-08-06 | — | — | EP | claimed |
| US-20250195682-A1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECHNOLOGIES B.V. (NL) | 2025-06-19 | — | — | US | claimed |
| EP-4171641-B1 | CONJUGATE OF GALNAC AND SAPONIN, THERAPEUTIC COMPOSITION COMPRISING SAID CONJUGATE AND A GALNAC-OLIGONUCLEOTIDE CONJUGATE | SAPREME TECH BV (NL) | 2024-10-30 | — | — | EP | claimed |
| EP-3897738-B1 | SAPONIN CONJUGATES | SAPREME TECH BV (NL) | 2024-01-24 | — | — | EP | claimed |
| US-20230302140-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | SAPREME TECHNOLOGIES B.V. (NL) | 2023-09-28 | — | — | US | claimed |
| US-20230293562-A1 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | SAPREME TECHNOLOGIES B.V. (NL) | 2023-09-21 | — | — | US | claimed |
| US-20230277680-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | SAPREME TECHNOLOGIES B.V. (NL) | 2023-09-07 | — | — | US | claimed |
| EP-4171642-A1 | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND AN ANTIBODY-SAPONIN CONJUGATE | Sapreme Technologies B.V. (NL) | 2023-05-03 | — | — | EP | claimed |
| EP-4171641-A1 | CONJUGATE OF GALNAC AND SAPONIN, THERAPEUTIC COMPOSITION COMPRISING SAID CONJUGATE AND A GALNAC-OLIGONUCLEOTIDE CONJUGATE | Sapreme Technologies B.V. (NL) | 2023-05-03 | — | — | EP | claimed |
| EP-4171647-A2 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | Sapreme Technologies B.V. (NL) | 2023-05-03 | — | — | EP | claimed |
| EP-4171643-A1 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | Sapreme Technologies B.V. (NL) | 2023-05-03 | — | — | EP | claimed |
| EP-4171646-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | Sapreme Technologies B.V. (NL) | 2023-05-03 | — | — | EP | claimed |
| EP-4126060-A1 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | Sapreme Technologies B.V. (NL) | 2023-02-08 | — | — | EP | claimed |
| EP-4117731-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | Sapreme Technologies B.V. (NL) | 2023-01-18 | — | — | EP | claimed |
| US-20220313834-A1 | IMPROVED ANTIBODY-OLIGONUCLEOTIDE CONJUGATE | SAPREME TECHNOLOGIES B.V. (NL) | 2022-10-06 | — | — | US | claimed |
| US-20220218837-A1 | DRUG CONJUGATE | SAPREME TECHNOLOGIES B.V. (NL) | 2022-07-14 | — | — | US | claimed |
| US-20220111066-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | SAPREME TECHNOLOGIES B.V. (NL) | 2022-04-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220313834-A1 | IMPROVED ANTIBODY-OLIGONUCLEOTIDE CONJUGATE | CD40, TNFSF10, IGSF11 | ST14 643/4885TACR1 781/4885OXTR 2529/4885 |
| US-20230293562-A1 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | ASGR1, HCCS, HAVCR2 | ST14 2970/4885TACR1 909/4885OXTR 1091/4885 |
| US-20260000783-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | EPCAM, CD47, FCGR3B | ST14 142/4885TACR1 2420/4885OXTR 4583/4885 |
| US-20230277680-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | CYP46A1, HCCS, DHCR7 | ST14 343/4885TACR1 3909/4885OXTR 4619/4885 |
| US-20220111066-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | EPCAM, CD47, EGFR | ST14 149/4885TACR1 1732/4885OXTR 4275/4885 |
| US-20220218837-A1 | DRUG CONJUGATE | OSTC, ADCY7, ADCY3 | ST14 1703/4885TACR1 940/4885OXTR 1483/4885 |
| US-20250195682-A1 | IMPROVED CELL-TARGETING BINDING MOLECULE | EPCAM, CD47, CD74 | ST14 239/4885TACR1 1201/4885OXTR 4526/4885 |
| US-20230302140-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | CYP46A1, HCCS, DHCR7 | ST14 343/4885TACR1 3909/4885OXTR 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.